Treatment-related mortality, relapse, disease-free survival, and death after transplantations for lymphoblastic lymphoma
| . | HLA-identical sibling transplant . | Autologous transplant . | P . |
|---|---|---|---|
| Treatment-related mortality* | |||
| 6 mo | 18 (10-27) | 3 (1-7) | .002 |
| 1 y | 22 (13-32) | 4 (1-8) | .0005 |
| 3 y | 25 (16-36) | 5 (2-10) | .0003 |
| 5 y | 25 (16-36) | 5 (2-10) | .0003 |
| Relapse* | |||
| 6 mo | 28 (18-38) | 30 (22-39) | .70 |
| 1 y | 32 (22-43) | 46 (37-55) | .05 |
| 3 y | 34 (23-45) | 52 (43-61) | .01 |
| 5 y | 34 (23-45) | 56 (45-65) | .004 |
| Disease-free survival† | |||
| 6 mo | 55 (43-65) | 66 (57-74) | .11 |
| 1 y | 46 (34-56) | 50 (40-58) | .61 |
| 3 y | 36 (24-48) | 42 (34-51) | .83 |
| 5 y | 36 (24-48) | 39 (30-48) | .82 |
| Survival† | |||
| 6 mo | 59 (48-68) | 75 (67-82) | .01 |
| 1 y | 49 (38-59) | 60 (52-68) | .09 |
| 3 y | 39 (29-49) | 46 (38-54) | .32 |
| 5 y | 39 (29-49) | 44 (36-52) | .47 |
| . | HLA-identical sibling transplant . | Autologous transplant . | P . |
|---|---|---|---|
| Treatment-related mortality* | |||
| 6 mo | 18 (10-27) | 3 (1-7) | .002 |
| 1 y | 22 (13-32) | 4 (1-8) | .0005 |
| 3 y | 25 (16-36) | 5 (2-10) | .0003 |
| 5 y | 25 (16-36) | 5 (2-10) | .0003 |
| Relapse* | |||
| 6 mo | 28 (18-38) | 30 (22-39) | .70 |
| 1 y | 32 (22-43) | 46 (37-55) | .05 |
| 3 y | 34 (23-45) | 52 (43-61) | .01 |
| 5 y | 34 (23-45) | 56 (45-65) | .004 |
| Disease-free survival† | |||
| 6 mo | 55 (43-65) | 66 (57-74) | .11 |
| 1 y | 46 (34-56) | 50 (40-58) | .61 |
| 3 y | 36 (24-48) | 42 (34-51) | .83 |
| 5 y | 36 (24-48) | 39 (30-48) | .82 |
| Survival† | |||
| 6 mo | 59 (48-68) | 75 (67-82) | .01 |
| 1 y | 49 (38-59) | 60 (52-68) | .09 |
| 3 y | 39 (29-49) | 46 (38-54) | .32 |
| 5 y | 39 (29-49) | 44 (36-52) | .47 |